Efficient and persistent transduction of exocrine and endocrine pancreas by adeno-associated virus type 8

Cheng, Henrique; Wolfe, Stephanie; Valencia, Valery; Keping Qian; Leping Shen; Phillips, M. Ian; Lung-Ji Chang; Zhang, Y. Clare
September 2007
Journal of Biomedical Science;Sep2007, Vol. 14 Issue 5, p585
Academic Journal
Efficient delivery of therapeutic proteins into the pancreas represents a major obstacle to gene therapy of pancreatic disorders. The current study compared the efficiency of recombinant lentivirus and adeno-associated virus (AAV) serotypes 1, 2, 5, 8 vectors delivered by intrapancreatic injection for gene transfer in vivo. Our results indicate that lentivirus and AAV 1, 2, 8 are capable of transducing pancreas with the order of efficiency AAV8 >>AAV1 > AAV2 ≥ lentivirus, whereas AAV5 was ineffective. AAV8 resulted in an efficient, persistent (150 days) and dose-dependent transduction in exocrine acinar cells and endocrine islet cells. Pancreatic ducts and blood vessels were also transduced. Extrapancreatic transduction was restricted to liver. Leukocyte infiltration was not observed in pancreas and blood glucose levels were not altered. Thus, AAV8 represents a safe and effective vehicle for therapeutic gene transfer to pancreas in vivo.


Related Articles

  • 116. The Proposed AAV Serotypes 10 and 11 Serologically Cross-React with AAV8 and AAV4. Vandenberghe, Luk H.; Miller, James R.; Gao, Gaung-Ping; Calcedo, Roberto; Wilson, James M. // Molecular Therapy;Jun2006, Vol. 13, pS47 

    Introduction: Vectors based on a variety of AAV isolates are currently being explored for application in gene therapy. This pursuit is driven by the fact that relatively subtle structural differences can dramatically affect vector biology in several ways relevant to gene therapy such as...

  • Cell Membrane-associated Heparan Sulfate Is a Receptor for Prototype Foamy Virus in Human, Monkey, and Rodent Cells. Nasimuzzaman, Md; Persons, Derek A // Molecular Therapy;Jun2012, Vol. 20 Issue 6, p1158 

    Foamy viruses (FVs) (spumaretroviruses) are good alternative to retroviruses as gene therapy vector. Despite four decades since the discovery of FV, its receptor molecule is still unknown. FV vector transduction of human CD34+ cells was inhibited by culture with fibronectin. Because fibronectin...

  • 250. Protection Against Huntington's Diease Progression: AAV-Mediated Delivery of Biotherapeutics. Kells, Adrian P.; Henry, Rebecca A.; Hughes, Stephanie M.; Faull, Richard L. M.; Connor, Bronwen // Molecular Therapy;Jun2006, Vol. 13, pS95 

    Advances in the development of adeno-associated viral (AAV) vectors for in vivo gene therapy have shown AAV vectors can safely direct the continuous, targeted production of biotherapeutics. This is promising for the treatment of neurological disorders like Huntington's disease where there is a...

  • 919. Gene Therapy for Duchenne Muscular Dystrophy Using a Gutted Adenovirus Expressing Utrophin. Deol, Jatinderpal R.; Gilbert, Renald; Danialou, Gawiyou; Bourget, Mylene; Joon-Shik Moon; Petrof, Basil J.; Nalbantoglu, Josephine; Karpati, George // Molecular Therapy;Jun2006, Vol. 13, pS354 

    Duchenne muscular dystrophy (DMD) is characterized by a mutation in the gene encoding a sarcolemmal protein, dystrophin (dys) and the deficiency of dys leads to progressive loss of muscle fibers. Gutted adenovirus (AdV) vectors are less immunogenic than their predecessors and have the capacity...

  • 814. Biomaterial-Mediated Retroviral Gene Delivery. Gersbach, Charles A.; Coyer, Sean R.; Le Doux, Joseph M.; Garcia, Andres J. // Molecular Therapy;Jun2006, Vol. 13, pS315 

    Introduction Inefficient and uncontrolled gene delivery has hampered the widespread efficacy of gene therapy. Biomaterial- mediated gene transfer represents a promising strategy to address these limitations by immobilizing the gene carrier onto a biocompatible substrate. This approach permits...

  • 740. A Novel Hybrid System Efficiently Expands AAV Packaging Capacity. Ghosh, Arka; Yongping Yue; Dongsheng Duan // Molecular Therapy;Jun2006, Vol. 13, pS286 

    The small packaging capacity is a long-standing hurdle limiting broad application of adeno-associated virus (AAV) in gene therapy. The trans-splicing and overlapping methods were developed recently to overcome this barrier. However, the trans-splicing method is highly dependent on the existence...

  • 103. A Screen for Host Cellular Proteins That Interact with Adeno-Associated Virus Capsid Proteins Reveals Proteins Involved in AAV8 Transduction. Akache, Bassel; Fuess, Sally; Grimm, Dirk; Kay, Mark A. // Molecular Therapy;Jun2006, Vol. 13, pS42 

    Vectors from adeno-associated virus (AAV) appear very promising for use in some gene therapy applications, due to their relative safety and sustained gene expression. Different serotypes of AAV have been isolated, each having different properties. For example, it has been shown that AAV-8...

  • A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8. Monteilhet, Virginie; Saheb, Samir; Boutin, Sylvie; Leborgne, Christian; Veron, Philippe; Montus, Marie-Françoise; Moullier, Philippe; Benveniste, Olivier; Masurier, Carole // Molecular Therapy;Nov2011, Vol. 19 Issue 11, p2084 

    Adeno-associated viruses (AAV) are small, nonenveloped single-stranded DNA viruses which require helper viruses to facilitate efficient replication. These recombinant viruses are some of the most promising candidates for therapeutic gene transfer to treat many genetic and acquired diseases....

  • Adeno-associated virus: from defective virus to effective vector. Gonçalves, Manuel A. F. V. // Virology Journal;2005, Vol. 2, p43 

    The initial discovery of adeno-associated virus (AAV) mixed with adenovirus particles was not a fortuitous one but rather an expression of AAV biology. Indeed, as it came to be known, in addition to the unavoidable host cell, AAV typically needs a so-called helper virus such as adenovirus to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics